<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02718885</url>
  </required_header>
  <id_info>
    <org_study_id>16035</org_study_id>
    <nct_id>NCT02718885</nct_id>
  </id_info>
  <brief_title>Gut Microbiome Mediated Effects of Inulin Supplementation on Mineral and Bone Metabolism in Hemodialysis Patients</brief_title>
  <official_title>Gut Microbiome Mediated Effects of Inulin Supplementation on Mineral and Bone Metabolism in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Urbana-Champaign</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Renal Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Urbana-Champaign</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of the study is to examine the changes within the gut microbiome after
      the supplementation of inulin and its effect on markers of mineral metabolism and bone
      turnover.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this randomized controlled cross-over study, twenty HD patients (10 male/10 female, aged
      20-80) will be recruited from local dialysis clinics in Champaign-Urbana, IL. After baseline
      testing, patients will be randomized to the intervention group or placebo group
      (maltodextrin). Patients will consume inulin (females 10g/day, males 15g/day) or maltodextrin
      (females 10g/day, males 15g/day) for one month, rest for two weeks (washout period), and
      continue with the other treatment (either inulin or maltodextrin) for another month. Outcomes
      will be assessed at the beginning of each period and after a month of supplementation at both
      periods.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mineral metabolism</measure>
    <time_frame>4 weeks</time_frame>
    <description>Plasma calcium, phosphorus and magnesium will be assessed by an blood-chemistry autoanalyzer at the beginning and end of each supplementation period. Additionally, parathyroid hormone and fibroblast-growth factor will be assessed by ELISA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone biomarkers</measure>
    <time_frame>4 weeks</time_frame>
    <description>Sclerostin, bone-specific alkaline phosphatase and osteoprotegerin will be assessed by ELISA kits at the beginning and end of each period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut-microbiota derived metabolites</measure>
    <time_frame>4 weeks</time_frame>
    <description>Free serum p-cresyl sulfate and indoxyl sulfate: serum (4ml) will be collected on midweek dialysis session and analyzed using an HPLC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiome</measure>
    <time_frame>4 weeks</time_frame>
    <description>Participants will be asked to collect a complete fecal sample at the beginning and end of Period 1 and 2. V4 regions of the bacterial 16S rRNA gene will be isolated and amplified. Sequencing will be done through Illumina Mi-seq V3 platform. General changes in bacterial diversity and taxa will be analyzed through the open software QIIME.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Bone Diseases, Endocrine</condition>
  <condition>Nutritional and Metabolic Diseases</condition>
  <arm_group>
    <arm_group_label>Maltodextrin</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Maltodextrin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inulin-type fructans</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Inulin</intervention_name>
    <description>Females will ingest 2 doses of 5g/inulin for a total of 10g/inulin/day for four weeks Males will ingest 2 doses of 7.5g/inulin for a total of 15g/inulin/day for four weeks</description>
    <arm_group_label>Inulin</arm_group_label>
    <other_name>Inulin-type fructans</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>Females will ingest 2 doses of 5g/maltodextrin for a total of 10g/maltodextrin/day for four weeks Males will ingest 2 doses of 7.5g/maltodextrin for a total of 15g/maltodextrin/day for four weeks</description>
    <arm_group_label>Maltodextrin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Receive HD therapy 3 days per week and for at least 3 months

        Exclusion Criteria:

          -  Sustained hypercalcemia (&gt;3months).

          -  Previous major gastrointestinal disease diagnosis (e.g., inflammatory bowel disease
             and celiac disease).

          -  Antibiotic treatment &lt; 2 weeks prior the start of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Wilund, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Urbana-Champaign</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kenneth Wilund, Ph.D.</last_name>
    <email>kwilund@illinois.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Illinois at Urbana-Champaign</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth R Wilund, PhD</last_name>
      <phone>217-265-6755</phone>
      <email>kwilund@illinois.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2016</study_first_submitted>
  <study_first_submitted_qc>March 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2016</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Urbana-Champaign</investigator_affiliation>
    <investigator_full_name>Kenneth Wilund</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>inulin-type fructans</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>gut microbiome</keyword>
  <keyword>mineral and bone disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Bone Diseases, Endocrine</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

